Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

ObjectivesTo evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).MethodsMulticentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following...

Full description

Authors: Martin-Varillas, JL; Sanchez-Bilbao, L; Calvo-Rio, V; Adan, A; Hernanz, I; Gallego-Flores, A; Beltran-Catalan, E; Castro-Oreiro, S; Fanlo, P; Martos, AG; Torre, I; Cordero-Coma, M; De Dios, JR; Garcia-Aparicio, A; Hernandez-Garfella, M; Sanchez-Andrade, A; Garcia-Valle, A; Maiz, O; Miguelez, R; Rodriguez-Montero, S; Urruticoechea, A; Veroz, R; Conesa, A; Fernandez-Carballido, C; Jovani, V; Mondejar, JJ; Gonzalez, OM; Alvarado, PM; Romero-Yuste, S; Rubio-Munoz, P; Pena-Sainz-Pardo, E; Garijo-Bufort, M; Demetrio-Pablo, R; Hernandez, JL; Blanco, R
Format: Article
Status:Published version
Publication date:2022
Country:España
Institution:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repository:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p15483
Online Access:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15483
https://ddd.uab.cat/record/283219
Access Level:Open access
Keyword:biological therapy
systemic vasculitis
autoimmune diseases
certolizumab pegol
Summary:ObjectivesTo evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).MethodsMulticentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year.ResultsWe studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6 +/- 11.7 years. The IMID included were: spondyloarthritis (n=43), Behcet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1),ConclusionsCZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.

Similar Items